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History
The Institute for Biomedical Research of Barcelona (IIBB) belongs to the CSIC and is 
associated to the “Institut d’Investigacions Biomèdiques August Pi i Sunyer” consortium 
(IDIBAPS). IDIBAPS belongs to the CERCA (Research Centers of Catalonia) and is one of 
the largest and most productive biomedical research institutes in Spain. 
The IIBB was created by the CSIC’s governing board on 28 February 1995 with three 
departments (Medical Bioanalysis, Pharmacology and Toxicology, and Neurochemistry) 
of the “Center for Research and Development” (CID) with the aim to join the IDIBAPS, 
together with the School of Medicine of the University of Barcelona, the Hospital Clínic of 
Barcelona and the Generalitat de Catalunya (Catalan Government). The staff of the institute 
remained at the CID until July 1999, when it moved to new premises at the Hospital Clinic 
(Rosselló 161, 6th and 7th floors). 
Favored by a space shortage at the IIBB, the CSIC and the Autonomous University of 
Barcelona (UAB) signed an agreement for the creation of a common Laboratory of 
Proteomics CSIC/UAB. The IIBB Structural and Biological Mass Spectrometry and 
Proteomic Unit moved to the UAB the end of 2005.
In November 2016 the Cardiovascular Research Center (CIC), a CSIC institute located in 
Hospital de Sant Pau (HSP) in Barcelona, was suppressed. Three of the CIC researchers 
joined then the IIBB, while remaining in HSP premises.
In June 2018 the CSIC created an Associated Unit named “Tumorigenesis Mechanisms and 
Tumor Progression” at the IMIM (Institut Hospital del Mar d’Investigacions Biomèdiques) 
through the IIBB. 
The departmental structure of the IIBB has been modified twice in order to adapt to 
successive strategic plans and at present is organized in four Departments: Cell Death 
and Proliferation, Cerebral Ischemia and Neurodegeneration, Experimental Pathology, and 
Neurochemistry and Neuropharmacology. 
IIBB members belong to six different Biomedical Network Research Centers (CIBER: CIBERNED, 
CIBERSAM, CIBEREHD, CIBERESP, CIBERCV or CIBERBBN) and also teach postgraduate 
programs in the University of Barcelona, thus contributing to the training of highly specialized 
professionals. 
IIBB former Directors 
Emilio Gelpí Monteys   (1995 – 2009)
Cristina Suñol Esquirol   (2009 – 2014)
José Carlos Fernández-Checa  (2014 – 2018)
Our mission 
IIBB is a basic biomedical research center whose mission is to advance the understanding 
and to promote translational research in the in the field of Health Sciences, in order to meet 
the demands of our society in diseases and therapeutic and surgical interventions of high 
incidence and social repercussion, such as neurological and psychiatric diseases, inflammatory 
processes and cell death. 
Our Aims
The objectives of the IIBB within IDIBAPS are therefore oriented towards the development of 
its own research in the field of Medical Sciences with a scientific activity focused on 
a. research and development that integrates basic researchers in close collaboration with 
clinical researchers 
b. the contribution to solving health care problems and 
c. enhance our training capabilities of the next biomedical scientists through postgraduate teaching.
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Laura Ferigle (Technician trainee)
Ada Bernaus (BSc student)
Neuroinflammation, in which activated glial cells 
(mainly microglia) are involved, is a key factor in the 
development of neurological diseases. Our working 
hypothesis is that the modulation of glial activation 
may be a therapeutic strategy to act against neuroin-
flammation and neuronal damage in these disorders. 
Consequently, it is critical to know the cellular and 
molecular mechanisms involved. 
In the last years, we have been studying the mec-
hanisms of control of the microglial inflammatory 
response, such as the CD200-C200R1 ligand-re-
ceptor pair (inhibitory mechanism) and the C/EBP 
family of transcription factors (master regulator of 
the expression of pro-inflammatory factors). We 
have also been evaluating the effect of parkinsonian 
neurotoxicants on glial cell function and the anti-in-
flammatory and neuroprotective properties of new 
compounds. We identified alterations in CD200 
and CD200R1 expression in the brain of multiple 
sclerosis and Parkinson’s disease patients, as well 
as in experimental in vivo models of these diseases, 
where a potential neuroprotective role of CD200R1 
agonists was suggested. In addition, using in vitro 
approaches, we found that parkinsonian neurotoxi-
cants impair the immune response of glial cells acting 
on cell metabolism, pointing out glial cell metabolism 
as an interesting target to modulate glial activati-
on. We also found that C/EBPbeta deficiency has a 
neuroprotective effect in an experimental model of 
multiple sclerosis and that C/EBPdelta is a repressor 
of alpha-synuclein expression.
At present, we are involved on the study of anti-in-
flammatory and neuroprotective effects of new 
compounds using in vitro and in vivo experimental 
models, with special attention to their action on our 
proteins of interest and glial cell metabolism. We are 
also interested on the development of in vitro human 
microglia models, such as microglia isolation from 
fresh post mortem brain tissue, monocyte-derived 
microglia-like cells and iPSCs-derived microglial cells 
from patients with neurological disorders and their 
corresponding controls. 
RESEARCH GROUPS
Department of Brain Ischemia and Neurodegeneration
Cellular Neurobiology
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The research objective is to find new therapeutic 
strategies to prevent or delay and ultimately to avoid 
the cognitive loss and dementia that may appear in 
the advances stages of life. Improvement in health 
care has propitiated an increase of the longevity ave-
rage. Unfortunately, there is a concomitant increase 
of age related diseases. Even though serious health 
Coral Sanfeliu Pujol (PI, Scientific researcher)
Cristina Suñol Esquirol (Ad honorem researcher)
Eduard Rodríguez-Farré (Ad honorem CSIC rese-
arch professor) 
Rubén Corpas Expósito (Postdoctoral researcher 
CIBERESP)
Elisa García Lara (PhD student European Project 
Targu Mures University)
Alaó Gatius Puchercós (Technician)
Núria Clotet Gispert (MSc in Neuroscience student)
Samuel Aguirre Infantes (MSc in Neuroscience 
student)
Iovana Solovastru (ERASMUS student Targu Mures 
University)
Ionut-Viorel Vlad (ERASMUS student Targu Mures 
University)
Anca-Cristina Staicu (ERASMUS student Targu Mures 
University)
Lars Andre Jager (Student Hochschule Fresenius)
Aging and Neurodegeneration
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epidemics such AIDS and the current COVID19, one 
next pandemic to worry about is Alzheimer’s dise-
ase (AD). AD is the main cause of dementia in our 
elders. The research is planned to find endogenous 
neuroprotective mechanisms to activate or reinforce 
through pharmacological or non-pharmacological 
treatments. One such mechanism is the axis SIRT1-
SIRT3. We had previously demonstrated in an AD 
mouse model that physical exercise restores decre-
ased levels of SIRT1 up to wild type mouse levels 
in parallel with neuroplasticity and neurocognitive 
improvement; furthermore, we demonstrated the 
pivotal neuroprotective action of SIRT1 by lentiviral 
gene expression in the AD mice. We also had proved 
that the SIRT1 activator natural molecule resveratrol 
is highly neuroprotective in AD mouse models. Next 
in 2019, we showed that middle-aged amateur rugby 
players have a preserved memory in comparison to 
men with low physical activity. Interestingly, investi-
gation of mRNA levels in whole blood of both cohort 
groups showed higher levels of SIRT1 and SIRT3 and 
improvement of downstream targets of oxidative 
stress and inflammation. These results reinforce the 
interest of SIRT1 as a neuroprotective hub target. 
We also delved into resveratrol promotion of prote-
asoma degradation of abnormal proteins, therefore 
establishing a new link between SIRT1 activation and 
neuroprotection against AD. We plan to continue 
these studies. Also we are investigating a new target 
against AD, the enzyme soluble epoxide hydrolase 
which inhibition increases the levels of its substrate, 
the epoxyeicosatrienoic acids (EETs). 
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Stroke is one of the leading causes of death or 
permanent disability. Treatments are based on re-
canalization therapies including mechanical throm-
bectomy and/or tissue plasminogen activator. Our 
team investigates the physiopathology of cere-
brovascular diseases, including stroke and chronic 
vascular disorders. A main focus of our research is 
the inflammatory and immune responses to brain 
damage. 
Our strategic objectives are: 
1. To identify the molecular signatures of the mi-
croglial response to brain injury after stroke and 
their role in stroke outcome. 
2. To find out the involvement of dendritic cells and 
other leukocytes infiltrating the brain tissue after 
stroke in tissue damage and repair. 
Anna M Planas Obradors (PI, CSIC Professor re-
searcher)
Carles Justicia Mercader (Tenured researcher)
Valérie Petegnief (Titulado Superior Especializado)
Leonardo Márquez Kisinousky (Titulado Técnico 
Superior) 
Mattia Gallizioli (Titulado Superior de actividades 
técnicas y profesionales, project)
Jordi Pedragosa Ollé (Titulado Superior de activi-
dades técnicas y profesionales, project)
Angélica Salas Perdomo (Titulado Superior Fundació 
Clínic)
Maria Arbizar Rovirosa (PhD student FPI)
Sara Figuerola Santamónica (PhD student UE-ITN)
Marina Purroy (PhD student AGAUR)
Judit Nova (Titulado Superior de actividades técnicas 
y profesionales, project)
Sara Eslava (Technician)
Amaia Otxoa de Amezaga (PhD student FPI)




3. To get insight into the interaction between the 
central nervous system, the immune system, and 
gut microbiota in cerebrovascular diseases. 
4. To characterise determinants of the crosstalk 
between brain resident microglia and perivascular 
macrophages with the vascular endothelium. 
5. To typify the impact of aging and co-morbid-
ities on brain pathology and on the impairment 
of the neurological function. To this end we work 
with experimental animal models, cell cultures, and 
human tissues. We conduct studies using imaging 
techniques, including MRI and confocal microscopy, 
flow cytometry, transcriptomics, histology, general 
cell and molecular biology techniques, and some 
behavioural studies. We collaborate with the Stroke 
Unit of Hospital Clinic with the view of carrying out 
translational research integrating the results of ex-
perimental models and clinical studies. Our ultimate 
aim is to contribute to discover novel druggable 
targets for therapeutic intervention in application 
to stroke and other cerebrovascular diseases. 
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The group studies the contribution of a family of 
proteins, the vitamin K-dependent proteins (VK-
DPs) and their receptors in human pathology. The 
idea that we have today is that the mechanisms of 
coagulation are integral to the body's response to 
injury and are part of the activation cascades that 
lead to inflammation and clotting. Our group studies 
the small group of vitamin K dependent proteins; a 
post-translational modification that it is known to 
occur in no more than twenty human proteins.
VKDPs are able to interact in a calcium-dependent 
manner with negatively charged membranes found 
in the activated endothelium or platelets and in the 
early stages of apoptosis. At the same time, VKDPs 
also interact with membrane receptors, acting as 
ligands in response to damage processes. We are 
particularly interested in two genes of this family 
(PROS1 and GAS6). GAS6 and PROS1 are special in 
interacting with receptor tyrosine kinases, therefore 
eliciting growth factor-like actions upon cells. In or-
der to study their biological function, we have used 
mouse models of haemostasia, atherosclerosis and 
cardiovascular disease. We have also studied these 
components in the context of human pathology, 
mainly cardiovascular pathology, but also autoim-
mune and liver diseases, among others. One aspect 
we have analysed is the genetic variants in GAS6 
and PROS1 genes and their functional implications. 
Recently we discovered a connection of this system 
with fibrosis formation in different tissues, including 
heart and the liver. Fibrosis is a central mechanism 
to several chronic pathologies. During 2019, this was 
our main research focus. 
 Pablo Garcia de Frutos (PI, Tenured researcher)
 Maria Cristina Areste Calero (Technician)
Helena  Cristobal Valero (Technician IDIBAPS)
Domenico Calafato (ERASMUS student)
Lorena Fernández de Larrea (Student)
Department of Cell Death and Proliferation
Hemostasis and Immunity
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This group investigates the molecular mechanisms of 
neuronal death to identify new therapeutic targets 
for the treatment of neurodegenerative diseases. Our 
team is also affiliated with the Center for Biomedical 
Research in Neurodegenerative Diseases, CIBERNED.
It is working on identifying molecular mechanisms 
of neurodegenerative diseases such as Alzheimer’s 
and Parkinson’s and on finding the necessary tools 
to prevent this.
Researchers have based its research on 
the hypothesis that neurodegeneration 
leads to alteration of the mitochondrial 
function. Studying the mitochondrial 
function, identifying the causes of its 
alteration and determining how it trig-
gers neurodegeneration are the group’s 
main objectives.
The group has discovered that a reduc-
tion in mitochondrial DNA content pre-
cedes the development of Alzheimer’s 
disease. It is now investigating the role 
of mitochondrial DNA transcription 
and replication in neurodegenerative 
diseases. 
Using a digital PCR method previously 
characterized in our laboratory, during 
the year 2019 we have investigated the 
relationship between replication, transcription and 
release of mitochondrial DNA in fibroblasts from pa-
tients with idiopathic and familial Parkinson's disease. 
The results obtained demonstrate that patients with 
Parkinson's disease, whether idiopathic or familial, 
manifest a decrease in replication accompanied by 
an increase in transcription of mitochondrial DNA. 
Furthermore, we have continued to investigate the 
relationship between the content of cell-free mi-
tochondrial DNA in the cerebrospinal fluid and the 
progression of Alzheimer's disease.
Ramon Trullás Oliva (PI, CSIC Research professor) 
Petar Podlesniy (Research scientist CIBERNED)
Maria Pedraza (Research scientist University of 
Göteborg)
Margalida Puigròs Serra (PhD student)
Georgia Papadimitriou (PhD student stage, National 
and Kapodistrian University of Athens)
Nuria Serra Barea (Technician CIBERNED)
Andrea Reparaz Suelves (Technician CIBERNED)
Molecular Mechanisms of Neurodegeneration
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Molecular Mechanisms of Cancer
Our group is a multidisciplinary team composed of 
basic and clinical researchers integrated into the Asso-
ciated Unit IIBB-IMIM (June 2018-present), a collabo-
ration agreement between IIBB and IMIM-Hospital del 
Mar. We have a long-lasting experience in the study 
of molecular mechanisms of cancer development 
and progression, with the final goal to identify new 
targets for cancer diagnosis and treatment. 
Pilar Navarro Medrano (PI, Tenured scientist)
Domenico Calafato (ERASMUS student)
Mireia Bachiller García (Student JAE Intro)
Our research has led to the identification of novel 
molecular mechanisms contributing to cancer pro-
gression, including:
1. The discovery of novel pathways for gene expression 
regulation in cancer, including the CPEB family of RNA 
binding proteins and the DEAD-box helicase Ddx6; 
2. The identification of a key role of Galectin-1 (Gal1) in 
promoting pancreatic carcinogenesis through activa-
tion of tumor-microenvironment crosstalk, emerging 
as a new target for cancer diagnosis and therapy. 
We have also shown novel functions of Poly(ADP)
ribose polymerases (PARPs) in cancer, with poten-
tial clinical translation. Although most of our studies 
have been focused on pancreatic cancer, one of the 
most aggressive tumors and the 3rd leading cause 
of cancer-related death, we are currently extending 
these studies to other cancers where these targets 
are also altered, like prostate and bladder tumors.
In the following years, we aim to translate our previ-
ous generated knowledge into clinical opportunities 
for cancer therapy and diagnosis. In particular, we 
aim to validate Galectin-1 inhibitors as novel cancer 
immunotherapy and to generate therapeutic tools 
based in DDX6 inhibition as cancer treatment. Mo-
reover, we will try to identify novel biomarkers for 
early cancer detection. Overall, our research will open 
new avenues for the management of cancer patients, 
leading to novel target-driven therapies and to the 
identification of new biomarkers for improved early 
diagnosis. 
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Our group has focused on the role of structural lipids 
in cell signaling and human disease. Our work has 
added a new dimension describing critical roles of 
cholesterol and cholesterol and sphingolipids (SL) in 
the regulation of cell death by targeting mitochondrial 
membranes, leading to the progression of prevalent 
human diseases, including fatty liver disease (FLD) 
progression to liver cancer as well as in major neu-
rodegenerative diseases, predominantly Alzheimer´s 
disease (AD) and lysosomal storage disorders, like 
Niemann-Pick type A and C. 
We have unravelled the role of mitochondrial cho-
lesterol trafficking in the above mentioned diseases 
and discovered the upregulation of STARD1, a mitoc-
hondrial cholesterol transporter responsible for the 
trafficking of cholesterol to the mitochondrial inner 
membrane (MIM). STARD1 is rather low in the liver, 
but it is remarkably induced in pathological states, 
including steatohepatitis, an advanced stage of 
FLD, which encompasses both alcoholic (ASH) and 
nonalcoholic steatohepatitis (NASH) characterized 
by inflammation, fibrosis and hepatocellular demise, 
that can progress to hepatocellular carcinoma (HCC). 
As a proof of concept for the role of STARD1 in liver 
disease, we have generated STARD1 floxed mice to 
develop different mouse lines with deletion of STAD1 
in hepatocytes and nonparenchymal cells (hepatic 
stellate cells and Kupffer cells). Its induction has been 
also identified as a critical player in drug-induced liver 
injury and emerges as a novel therapeutic target to 
protect against acetaminophen hepatotoxicity. Similar 
to the liver diseases, we have described recently the 
induction of STARD1 in patients with AD and Down 
Syndrome—a genetically determined form of AD-- 
while mice with genetic deletion of STAD1 in neurons 
are resistant to diet-induced AD-like symptons. 
We have also investigated the role of SL in liver di-
seases, and have identified acid sphingomyelinase as 
a mechanism for the rapid generation of ceramide 
in specific acidic compartments in both ASH and 
NASH. Finally, our recent observations described 
a previously unrecognized role for sphingomyelin 
synthase 1 in the induction of hepatocyte pyroptosis 
as a requirement for NASH progression.
José Carlos Fernández-Checa (PI, CSIC Research 
Professor)
 Carmen García Ruiz (Scientific researcher)
 Vicent Ribas Serra (Researcher, project)
 Ana Moles Fernández (Researcher Ramón y Cajal 
fellow)
Laura Conde de la Rosa (Researcher CIBER)
 Raquel Fucho Salvador (Postdoctoral researcher 
Juan de la Cierva fellow)
 Naroa Insausti Urkia (PhD student FPI/FPU)
David Robles Sánchez (PhD student FPI)
Estel Solsona Vilarrasa (PhD student FPU)
Paloma Ruiz Blazquez (Student JAE Intro)
Alberto Edo Pérez (Student JAE Intro)
Rubén Mollá (Student JAE Intro)
Sandra Torres Núñez (Technician)
Susana Núñez Pozuelo (Technician)
Valeria Pistorio (Stage)
Laura Martínez Domingo (Technician trainee)
Gemma Torrodà (Technician trainee)




The proto-oncogen H-Ras codifies for two proteins, 
p21 H-Ras is (p21) and p19 H-Ras (p19), indicating that 
the complete function of this proto-oncogen is driven 
by the combination of those two proteins. P19 has a 
different function from p21. We have characterized 
p19 H-Ras and our results indicate that: a) p19 is not 
found at the cytoplasmic membrane and present a 
perinuclear staining; b) p19 binds to RACK1; c) p19 
also binds to p73α y p73β, which are tumor suppres-
sors members of the p53 family, but p19 shows no 
binding to p53; d) p19 up-regulates TCTP, a guano-
sine exchange factor (GEF) for Rheb, and hipo- and 
hyperphosphorylates Akt and ERK, respectively; e) 
p19 up-regulates the following miRNAs expression: 
mir-342, mir-206, mir-330, mir-138 and mir-99b; f) 
the p19 overexpression induces G1/S delay, that in 
combination with the hypophosphorylation of Akt 
maintains the cell in a reversible quiescence and 
prevents the cell to undergoes to apoptosis. We have 
published that IDX and the silencer rasISS1 can form 
a secondary structure of stem-loop that is regulated 
by the p68 RNA helicase. 
More Recent Results:
P19G12S Costello Syndrome mutants show a clear 
upregulation of miR-374, miR-126, miR-342, miR-330, 
miR-335 and let-7. 
We provided strong evidence for the participation 
of p68 RNA helicase in mTOR regulation. In detail, 
depletion of this helicase decreases cell growth and 
activates the mTOR/MDM2 cell survival mechanism, 
which ultimately leads to inhibition of the pro-apop-
totic activity. p68 RNA helicase downregulation 
strongly stimulates 4E-BP1 phosphorylation, thereby 
provoking activation of cap-dependent translation. 
Interestingly, p68 RNA helicase depletion decreases 
cell growth while activating the mTOR/MDM2 cell 
survival mechanism. As MDM2 is a known negative 
regulator of p53, we infer that the activation of the 
cell survival mechanism may result in inhibition of the 
pro-apoptotic factor p53. Finally, p68 RNA helicase 
depletion activates cap dependent translation and 
inhibits c-MYC IRES-mediated translation.
Results 2019 and future objectives:
We show that an important RNA sequence region, 
encompassing a mixed exon-intron Hairpin-Loop (also 
labelled as IDX-rasISS1), of the H-Ras pre-mRNA may 
contain a ncRNA that regulates p68 RNA helicase. 
Moreover, upregulation of the Hairpin-Loop produ-
ces similar effects to p68 RNA helicase-mediated 
interference. This latter finding led us to conclude 
that the alternative splicing exon IDX from H-Ras, 
together with the immediately downstream intron 
sequences, contains a mixed exon/intron ncRNA 
whose expression is regulated by the alternative 
splicing decisions.
Further studies are directed to elucidate the structure 
of this exon/intron RNA ncRNA containing the IDX 
H-Ras exon and the role of p68 RNA helicase on this 
ncRNA regulation. 
Montserrat Bach Elias (Scientific researcher)
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Our group focuses its research on the study of intra-
cellular and intercellular mechanisms that are activated 
in response to injury, particularly in liver and neurode-
generative diseases as well as processes of carcino-
genesis. The ultimate goal is a better understanding 
of the signaling involved in specific pathologies which 
allowing the development of therapeutic interventions 
to improve the treatment of human disease.
The main lines of research we address are:
• Therapeutic targets in Alzheimer's disease (Dr. Anna 
Colell).
• Mechanisms in liver inflammation and fibrosis (Dr. 
Montserrat Marí).
• Therapies in hepatocellular damage and cancer (Dr. 
Albert Morales).
During 2019 our main contributions has been to de-
monstrate the important role in Alzheimer disease of 
reactive oxygen species (ROS) via oxidative inactiva-
tion of amyloid beta-degrading proteases caused by 
cholesterol-enhanced mitochondrial stress (de Dios et 
al, Redox Biol. 2019). These results have contributed 
to explain the mitochondrial control of autophagy 
and its regulation by oxidative stress relevant not 
only to neurodegenerative diseases but also in other 
cardiovascular, chronic kidney and liver pathologies.
Moreover, our group has participated in proposing 
nutraceuticals rich in omega-3 fatty accids to impro-
ve complications of advanced chronic liver diseases 
and characterized the role of the GAS6/AXL axis in 
the development of non-alcoholic steatohepatitis 
(NASH) and liver cancer. 
 Albert Morales Muñoz (PI, Tenured scientist)
 Anna Colell Riera (Tenured scientist)
Montserrat Marí García (Tenured scientist)
Estefania de Gregorio Robles (Postdoctoral 
researcher)
Anna Tutusaus López (Postdoctoral researcher)
Blanca Cucarull Martínez (PhD student FPU)
 Cristina De Dios Conde (PhD student FPU)
 Vicente Roca Agujetas (PhD student)
 Laura Rebeca Lestón Pinilla (MSc student)
Miguel Subías Burrel (MSc student)
Signalling in Cell Damage and Cancer
Roca-Agujetas V, de Dios C, Lestón L, Marí M, Morales A, 
Colell A. Recent Insights into the Mitochondrial Role in 
Autophagy and Its Regulation by Oxidative Stress. Oxid 
Med Cell Longev. 2019;2019:3809308. Published 2019 
Nov 4. doi:10.1155/2019/3809308
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De Dios C, Bartolessis I, Roca-Agujetas V, et al. Oxidative in-
activation of amyloid beta-degrading proteases by choleste-
rol-enhanced mitochondrial stress. Redox Biol. 2019;26:101283. 
doi:10.1016/j.redox.2019.101283
Roca-Agujetas V, de Dios C, Lestón L, Marí M, Morales A, Colell A. Recent 
Insights into the Mitochondrial Role in Autophagy and Its Regulation 
by Oxidative Stress. Oxid Med Cell Longev. 2019;2019:3809308. Pu-
blished 2019 Nov 4. doi:10.1155/2019/3809308
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Research and development in methods and tech-
nologies related to the study of protein expression 
in humans and other organisms. Main areas of rese-
arch include quantitative proteomics, the study of 
post-translational modifications (phosphoproteome, 
acetylome and ubiquitinome), with a special interest 
in biological fluids, and the application of Proteomics 
on wastewater-based epidemiology.
The research group is at the Autonomous University of 
Barcelona’s campus in the context of an agreement CSIC-
UAB to establish the LP-CSIC/UAB shared laboratory.
We focus our efforts on the discovery of new protein 
markers of disease, mainly in the area of immuno-
logy, microbiology and environmental epidemiolo-
gy. During the last years, we built an open-access 
database of post-translational modification sites in 
the primary human T cell including their dynamics 
during activation. Recently, in collaboration with a 
leading group in environmental sciences, we started 
a new line in sewage water epidemiology showing 
for the first time the monitorization of human protein 
biomarkers in this media.
The group is a member of ProteoRed, the Spanish net 
of Proteomics laboratories under the umbrella of the 
ISCIII. As part of this network our laboratory contribu-
tes its experience on the analysis of post-translational 
modifications and participates in different initiatives 
within the net, such as The Human Proteome Project, 
an international multicentre project for the descripti-
on of the human proteome sponsored by the Human 
Proteome Organization (HUPO).
Our research implies an important component of met-
hodological and technological development mainly 
in the field of capillary liquid chromatography, mass 
spectrometry and bioinformatics. The main issues 
addressed include the characterization of post-trans-
lational modifications, the quantitative analysis of 
proteomes and de novo protein identification.
Our goal is to make immediately available the results of 
our research and development tasks to other projects 
and to the scientific community at large through a 
quick and transparent transfer of the methodologies 
to the IIBB Proteomics Services Unit.
Joaquín Abian Moñux (PI, Scientific researcher)
Montserrat Carrascal Pérez (Tenured scientist)
Oscar Gallardo Román (Técnico Superior, project)
Teresa García Berrocoso (Technician PTA)
Vanessa Casas López (Técnico superior de apoyo 
a la investigación UAB)
Department of Experimental Pathology
Biological Mass Spectometry and Proteomics
Carrascal el al. Sci Total Environ. 2020, 747:141145.
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Our group focuses on patho-physiological aspects 
of cardiac excitation-contraction coupling and ar-
rhythmogenesis.
Our goal is to improve the understanding of key gene-
tic and molecular factors underlying the development 
of pathological changes in cardiac contraction and 
rhythm using patch-clamp technique and confocal 
calcium imaging in situ and in vitro.
Leif Hove Madsen (PI, Tenured researcher)
Sergi Casabella Ramon (PhD student FPU)
Saray Varona Alvarez (Technician)
Hildegard Colino Lage (Technician)
Maria del Carmen Tarifa Lora (Technician)
Currently, funded projects and research collaborati-
ons are focusing on: 
1. The functional role of single nucleotide polymor-
phisms associated with risk of atrial fibrillation.
2. Remodeling of adenosine receptor function on 
in patients with atrial fibrillation and its role in the 
development of abnormal calcium handling.
Cardiac Rythm and Contraction 
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Lipids and Cardiovascular Pathology
Our research group focuses on: 
1. Search of new molecular mechanisms underlying 
abnormal cholesterol accumulation in the vasculature 
to find innovative treatments in atherosclerosis.
2. Identification of new peptidic and omic biomarkers 
useful in the detection of mechanisms underlying 
cardiovascular disease. 
The group has been pioneer in identifying the main 
processes involved the formation of foam cells 
from smooth muscle cell (SMC) origin. We showed 
that SMC-foam cells acquire a phenotype highly 
prothrombotic that plays a crucial role in plaque 
destabilization and evolution towards clinical events. 
We have consistently demonstrated that the li-
poprotein receptor, LRP1, through its pathological 
function of facilitating the transfer of cholesterol 
from atherogenic lipoproteins to vasculature and 
myocardium, contributes to the onset and deve-
lopment of several diseases of great prevalence in 
our society such as atherosclerosis, ischemic and 
diabetic myocardiopathies. In addition, the group 
has now an extensive productive work identifying 
new proteic and epigenomic biomarkers useful to 
improve the diagnosis and prognosis of cardiovas-
cular and metabolic diseases. 
Currently, we are investing a big effort to develop 
new compounds to target SMC and cardiomyocyte 
cholesterol loading through regulation of LRP1 inte-
raction with atherogenic lipoproteins. Currently, we 
have available in the group peptides and antibodies 
with proven efficacy in atherosclerosis that could 
be potentially useful in several cardiomyopathies. 
To advance these compounds towards the clinics, 
we have established strategical collaborations with 
clinicians from SantPau’s and other national and in-
ternational traslational groups. 
Our specific goals for the next future are to inte-
grate genomic and functional in vivo studies to 
validate LRP1 as a new therapeutical target and 
potential biomarker in cardiometabolic diseases; 
to maintain and amplify relationship with expert 
groups regarding translation in cardiometabolism; 
to maintain and strengthen national and internati-
onal collaborations to set up future applications for 
European funding; to advance in collaborations with 
companies wth the aim of developing new products 
useful for prognosis, diagnosis and treatment of 
cardiometabolic diseases.
Concepción Vicenta Llorente Cortés (PI, Tenured 
scientist)
Aleyda Benítez Amaro (PhD student ISCIII)
David De Gonzalo Calvo (Postdoctoral researcher 
Juan de la Cierva fellow)
Jesús Eduardo García Rodríguez (Student JAE 
Intro)
Albert Coloma (BSc student University of Vic)
Àngels Solanelles (Student University of Lleida)
Yazmin Estela Torres (Predoctoral stage, Instituto 
Nacional de Cardiología, Universidad de México) 
Thalia Belmonte (Predoctoral stage, University 
of Cádiz)
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Mechanisms of Damage and Recovery in Ischemia
Our research program is mainly focused on:
-The identification of the mechanisms associated with 
regeneration, prevention, and monitoring of ische-
mia/reperfusion damage in abdominal pathologies. 
-Development and application of new therapies aimed 
at preventing tissue damage and promoting regene-
ration (based on pharmacological, gene delivery, cell 
therapy or nanotechnological approaches). 
Specifically, the goals pursued on 2019 have been 
related to the specific objectives in the national, FIS 
and European projects, led by the group’s principal 
investigators:
1. The role of macrophage phagocytosis in fibrosis 
and the development of a new therapy of genetically 
modified macrophages to reduce renal fibrosis.
2. The development of new organ preservation solu-
tions and strategies to prevent ischemia/reperfusion 
injury associated with liver transplantation.
3. The use of polyethylene glycols as therapeutic 
tool for the management of secondary complicati-
ons associated with acute pancreatitis and pancreas 
transplantation.
Georgina Hotter Corripio (PI, Scientific researcher)
Priscila Calle Hinojosa (PhD student)
Ana Ferrero Andrés (PhD student)
 Emma Folch Puy (Titulado superior especializado)
 Mª Ángeles Muñoz Herrero (Technician)
Arnau Panisello (Researcher)
 Joan Rosello Catafau (Ad Honorem researcher)
Riu Gonçalo Teixeira Da Silva (PhD student Marie 
Curie)
 Soraya Játiva (Reseracher, project)
Selene Torrico (PhD student, project)
Miriam García Boscá (Technician, project)
4. The development and industrial application of the 
above objectives through contracts and/or partici-
pation in the group’s “spin offs”.
Experimental models in vitro and in vivo in rat/mouse 
include models of acute renal failure and chronic renal 
disease (renal fibrosis), acute pancreatic inflammati-
on, hepatic and pancreatic ischemia reperfusion, and 
organ preservation in experimental transplantation.
The members of the group are part of CIBER groups 
from two areas:  Hepatic and digestive diseases 
(CIBEREHD) and Bioengineering, Biomaterials and 
Nanomedicine (CIBER-BBN). 
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Our group investigates key aspects of vascular 
biology, atherothrombosis and myocardial pat-
hophysiology geared towards the characterization 
of the cellular and molecular mechanisms involved 
in the onset, progression and complication of 
atherotrombotic diseases (ischemic heart dise-
ase (IHD) and peripheral artery disease (PAD)), 
abdominal aortic aneurysm (AAA) and cardiac 
hypertrophy. The group analyses the role of NR4A 
nuclear receptors, in particular NOR-1 (NR4A3), 
and lysyl oxidases (LOX) in these pathologies using 
multidisciplinary and translational approaches. 
Our ultimate goal is to identify novel therapeutic 
targets and biomarkers to better manage these 
highly prevalent diseases. 
The specific objectives pursued are: 
1. Characterization of new molecular mechanisms 
underlying vascular dysfunction in IHD, PAD and AAA.
2.  Identification of new proteins/structural genes 
modulating critical cell functions (migration, proli-
feration, survival and apoptosis), in particular, those 
regulated by NR4A receptors and LOX.
3. Development and validation of new animal mo-
dels for cardiovascular diseases, in particular, those 
related to NR4A receptors and LOX. 
4. Analysis of the mechanisms underlying vascular 
calcification in advanced atherosclerosis and its 
potential pharmacological modulation, focusing on 
the contribution of LOX and NR4A receptors. 
5. tudy of the role of NR4A receptors modulating 
cardiac function, calcium homeostasis and cardi-
oprotection.
Our findings in 2019 have uncovered (i) the relevant 
role of NOR-1 in the pathological remodelling involved 
in hypertensive cardiac hypertrophy, establishing 
a new mouse model, for this disease, and (ii) how 
NR4A receptors participate in the signalling pathway 
of CD69, an immunomodulatory molecule that we 
identified as a new receptor for oxidized LDL and an 
early predictor of subclinical atherosclerosis. 
José Martínez González (PI, Tenured researcher)
 Laia Cañes Esteve (PhD student AGAUR)
Carme Ballester Servera (Technician) 
Judith Alonso Nieto (Postdoctoral researcher 
CIBERCV)
Saray Varona Álvarez (Postdoctoral researcher 
CIBERCV)
Vascular Biology and Atherosclerosis
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Our research group focuses on the study of the 
regulatory mechanisms of inflammation and fibro-
sis using models acute pancreatitis and idiopathic 
pulmonary fibrosis.
• Exosomes in the progression of inflammation in 
acute pancreatitis
We have developed experimental models of acute 
pancreatitis to evaluate the involvement of exo-
somes and extracellular vesicles in cell signalling 
between the pancreas and lung during the inflam-
matory response to pancreatic damage. We have 
demonstrated that, in addition to soluble mediators, 
there are several populations of exosomes released 
by the pancreas and liver that trigger the inflam-
matory activation of lung macrophages in severe 
forms of the disease. Analysis of the content of these 
exosomes allows us to design different strategies 
focused on controlling their effects in order to limit 
the progression of inflammation during severe acute 
pancreatitis.
• Cell therapy for the treatment of pulmonary diseases
We have developed a cell therapy based on the al-
veolar type II cells transplantation to treat idiopathic 
pulmonary fibrosis. We evaluated this therapy in 
patients affected with idiopathic pulmonary fibrosis 
and our results showed that this therapy was safe 
and able to slow down the disease progression. In 
an animal model of pulmonary fibrosis, we showed 
that this cell therapy recovered different proteins of 
pulmonary surfactant improving their lung capacity. 
At present, our research is focused on the mecha-
nisms on how alveolar type II cells are able to induce 
changes in the lung microenvironment as well as to 
induce the regeneration of fibrotic lung. The analysis 
of these mechanisms will allow us to improve this 
therapy not only for pulmonary fibrosis but also for 
other lung diseases.
Daniel Closa Autet (PI, Tenured scientist)
Anna Serrano Mollar (Researcher)
Luis Ignacio Sánchez (Technician)
 Aina Areny Balageró (PhD student)
Regulation of Inflammation
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Multiple sclerosis is a degenerative disease of the 
central nervous system that mainly affects young 
adults, especially women. It is a chronic inflammatory 
disease characterized by damage to the axons and 
a loss of myelin from neurons in the brain and spinal 
cord. This occurs as a result of infiltration by white 
blood cells (lymphocytes and macrophages) and 
results in the loss of neurological functions. To find 
new therapies, researchers must understand how 
this inflammation works.
The Molecular Neuropharmacology group focuses its 
work on the analysis of phosphodiesterases, enzymes 
involved in neuroinflammation. We use cell lines and 
primary cultures of macrophages, as well as a multiple 
sclerosis model in mice, experimental autoimmune 
encephalomyelitis (EAE), to find new therapeutic 
targets to treat this disease. Greater knowledge of 
the metabolic pathways involved and their alterations 
will help us identify new drugs capable of modifying 
the progression of the disease.
We have previously observed that some phospho-
diesterases (enzymes that degrade phosphodiester 
bond in intracellular messengers, cyclic AMP and/
or cyclic GMP) involved in neuroinflammation are 
expressed differently according to the sex of the 
animals. We observed a significant reduction of 
clinical symptoms when mice with EAE are treated 
chronically with an inhibitor of phosphodiesterase 7, 
an enzyme specific for cAMP. In the spinal cord of 
these treated mice, changes in the messenger RNA 
levels of some phosphodiesterases were seen, sug-
gesting a potential treatment for this disease.
Our research group studies the involvement of the 
cAMP cascade in the polarization of microglia and 
macrophages toward anti- or pro-inflammatory 
phenotypes (M1 or M2 respectively) both in cell 
culture -cell lines and primary cultures- and in the 
CNS of EAE mice. By using different cAMP analogs 
we have been able to study the influence of cAMP 
in the polarization of macrophages toward different 
M2 populations in both macrophage cell lines and 
primary cultures.
Guadalupe Mengod (CSIC Professor research)
Roser Cortés Colomé (Research scientist)
Mª Teresa Vilaró Comas (Tenured scientist)
Susana Muñoz Morales (Technician CIBERNED)
Doga Tuna (BSc student University of Bilkent, 
Turkey)
Sena Ferah (BSc student University of Canakkale 
Onsekiz Mart, Turkey)
Department of Neurochemistry and Neuropharmacology
Molecular Neuropharmacology
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The Systems Neuropharmacology group examines the 
brain circuits and neuronal elements involved in the 
physiopathology and treatment of major depression, 
schizophrenia and Parkinson disease. It also explores 
neurotransmission processes and brain physiology 
in genetic and pharmacological models of neurolo-
gical and psychiatric disorders, in order to identify 
new therapeutic targets. The group is internationally 
recognized for their contributions to the Neuropsyc-
hopharmacology field, which have helped to improve 
treatments for major depression. Likewise, the group 
has also examined the involvement of thalamo-cor-
tical circuits in the pathophysiology and treatment 
of psychotic disorders, including schizophrenia, a 
research line contributing to the identification and 
development of antipsychotic drugs. The groups has 
also pioneered the use of oligonucleotide strategies 
to study the pathophysiology of major depression 
and to develop fast-acting antidepressant treatments, 
overcoming the limitations of current antidepressant 
drugs, an approach also currently focused on the 
study of Parkinson’s disease. Along these lines, in 
2019 the group has completed a series of studies, 
including, among others. 
Francesc Artigas Pérez (PI, CSIC Professor researcher)
Analía Bortolozzi Biassoni (Tenured reasercher)
Anna Castañé Forn (Researcher)
Noemí Santana Ramos (Researcher CIBERSAM)
Maurizio Riga Postdoctoral (researcher IDIBAPS)
Mireia Tarrés Gatius (PhD student AGAUR CSIC/
IDIBAPS)
Rubén Pavía Collado (PhD student IDIBAPS)
Elena López Terrones (PhD student FPI)
Lluís Miquel Rio (PhD student IDIBAPS)
Sharon Manashirov (Collaborating researcher (mi-
CURE&Weizmann Institute of Scienceen, Rehovot 
Israel))
Leticia Campa Montobbio (Specialized technician 
in HPLC) 
Verónica Paz Silva (Technician CIBERSAM)
Raquel Rodríguez Aller (MSc student)
Unai Sarriés Serrano (MSc in Neuroscience student)
Carla Orta De Palau (Undergraduate student Les-
tonnac School of Barcelona)




1. Development of a mouse model of depression 
based on the RNAi-induced knockdown of astroglial 
glutamate transporters, together with the neuroc-
hemical and electrophysiological characterization 
of the neurobiological background in different brain 
areas. 
2. Study of the antidepressant-like actions of the 
siRNA-induced selective reduction of the expression 
of the K+ channel TASK-3 in serotonergic and nora-
drenergic neurons of the brainstem. 
3. Study of the actions of the fast-acting antidepres-
sant drug ketamine on the activity of thalamic and 
cortical neurons, as well as in brain oscillatory activity, 
in order to characterize the brain circuits involved in 
its psychotic-like and antidepressant actions. 
Ongoing studies are focused on the study of the 
role of α-synuclein in the control of monoaminergic 
activity, the neurobiological mechanisms involved in 
the antidepressant actions of ketamine and the role 
of glutamate-serotonin interactions in antidepressant 
mechanisms. 
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The IIBB imaging facility provides services and training 
to researchers from the IIBB, CSIC, Clinical Campus, 
and other public or private research institutes on 
microscopy and image analysis. This facility includes 
a set of state-of-the-art equipment and techniques 
to perform the experiments requested by the diffe-
rent research groups. It provides technical assistance 
from the design of experiments to the analysis of the 
results obtained. 
In 2019, the IIBB’s microscopy service provided 2010 
hours of service, of which 137 hours to users outside 
the center.
In November 2019, a Spinning Disk microscope was 
acquired from ANDOR (Oxford Instruments) with FE-
DER, CSIC and IIBB funding. This microscope allows 
to perform Live Imaging experiments and advanced 
microscopy techniques such as FRET, FRAP and 
photoactivation, among others.
Staff/contact:
• PI of the Facility: Joan Serratosa Serdà.
• PI of Confocal Microscopy: Ramón Trullàs Oliva.
• PI of Estereological microscope: Roser Cortés.
Services offered:
• Design of experiments related to optical microscopy 
• Image acquisition on different equipments.
• Performing advanced microscopy techniques (live 
imaging…).
• Training in the use of equipment.
•  Image processing and analysis.
• Interpretation and presentation of data obtained 
for scientific papers, conferences, dissemination…
Applications:
• Wide-Field microscopy (bright field, dark field, 
phase contrast, epifluorescence)
• Confocal microscopy with laser scanning
• Confocal microscopy with spin disk
• Stereology
• In vivo experiments with live cells 
•  Image analysis and image processing
Equipment:
• Vertical direct fluorescence Nikon Eclipse E 1000 
microscope
• Inverted fluorescence microscope Olympus IX70
• Vertical light microscope Zeiss Axioplan
•  Vertical direct fluorescence microscope Olympus 
BX51 for stereology
• Inverted fluorescence microscope Leica DMI 4000B
• Light macroscope Wild M420
• Vertical confocal microscope Leica TCS SPE
• Andor Dragonfly Spinning disk




The Histology Unit offers the possibility to prepare 
tissue samples using different techniques. It provides 
service and training to scientific and technical person-
nel of the IIBB, but it is also open to external users.
Staff/Contact:
PI of the Facility: Roser Cortés Colomé.
Technician: Luís Ignacio Sánchez López 
Techniques and Equipment: 
Tissue embedding in paraffin: 
• Programmable embedding station Shandon Citadel 
1000
• Wax dispenser Kunz
• Cold plate Kunz 
Tissue Sectioning:
• Leica VT 1200S vibratome (for fresh tissue)
• Microtome-cryostat Microm HM500 (for frozen 
tissue)
• Microtome-cryostat Microm HM550 (for frozen 
tissue) 




The Tissue Culture Facility of the IIBB, located in 
the seventh floor, is a Biosafety II laboratory used 
exclusively by the research groups of the IIBB. It is 
equipped with the basic devices necessary to obtain 
and maintain cell cultures in a laboratory: biologi-
cal safety cabinets, CO2 incubators, centrifuges, a 
water bath, inverted microscopes, a fluorescence 
microscope connected to a camera, a cell counter 
and an autoclave. In addition, an anoxic work station 
and a hypoxia incubador are available for hypoxia/
anoxia experiments. A gas station, located outside 
the laboratory, is responsible for the supply of the 
different gases needed in the laboratory: CO2, N2 and 
carbogen. Users work with primary cultures and cell 
lines from human and animal origin.
Albert Parull, a technician is in charge of the daily 
maintenance of the laboratory: supervision of gases 
levels, proper functioning of the incubators and la-
minar flow cabins, appropriate waste disposal and 
control of the supplies. Annual maintenance of the 
devices is performed by external specialized com-
panies.
The laboratory also has a scientific supervisor. Dr 
Valérie Petegnief is responsible for supervising the 
technician’s work, takes care of the appropriate use 
of the laboratory and cares for users’ needs. The 
number of users is around 35. 
Tissue culture
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CSIC Proteomics Facility providing technology and 
expertise for large-scale quantitative and qualitative 
analysis of proteomes as well as for the identification 
and quantification of target peptides and proteins. 
The Proteomics Facility also provides scientific and 
technical advising and analytical services on peptide 
and protein characterization to external public and 
private research groups. 
The laboratory occupies 90 m2 and houses four mass 
spectrometers, several conventional and nanocapi-
llar liquid chromatographic systems, an automatic 
digestor, a preparative IEF system, and the necessary 
infrastructure to perform small and large 2D gels 
and for image acquisition and analysis. It also has 
all the common laboratory gear required to perform 
its tasks (centrifuges, freezers, etc.).
Common tasks are related with the identification of 
biomarkers in biological fluid, cells and tissues, often 
in relation to pathological states, using 2D-PAGE 
or capillary chromatography for isolation and mass 
spectrometry for characterization. In addition to 
proteomics-focused applications, some clients are 
using the available infrastructure for the analysis of 
other bioorganic compounds in areas such as en-
vironmental and clinical research and metabolomics 
This IIBB Facility and the IIBB Biological Mass Spec-
trometry and Proteomics Research Unit are currently 
integrated in the CSIC/UAB Proteomics Laboratory 
(LP-CSIC/UAB).
Our services include:
- Molecular weight analysis by MS-MALDI TOF and 
electrospray-MS
- Protein identification by peptide mass fingerprinting
- Protein identification by tandem mass spectrometry 
(MS/MS) using nESI-MS/MS and LC-MS/MS
- De novo sequencing
- Gel electrophoresis (1D and 2D-PAGE) and Diffe-
rential In Gel Electrophoresis (DIGE)
- Protein and peptide quantification using isotopic 




Since 2012, the facility holds an ISO-9001 certifi-
cation (Currently, ISO-9001:2015). Management of 
the analytical protocols, of the internal and external 
personnel, as well as the interaction with customers 
and suppliers is described in the documents associa-
ted to this Quality management system certification. 
Proteomics
IMS images showing pattern distribution corresponding 
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nally-Selective Knockdown of Astroglial Glutamate 
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15. García E, Aguirre S, Clotet N, Corpas R, Slevin 
M, Sanfeliu C. 2019. Mechanisms of monomeric C 
Reactive Protein inducing neurodegeneration. FENS 
Regional meeting 2019. Belgrade, Serbia.
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16.  Garcia P. 2019. Coagulation Factors Crosstalk with 
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Haemostasis 2019. Glasgow, United Kingdom.
17. López E (speaker), Artigas F, Celada P. 2019. 
Different responses of piramidal neurons in prelim-
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de Ideas para Jóvenes Investigadores Cibersam. 
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edad Catalana de Inmunologia. Barcelona, Spain.
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mitochondrial DNA in rapid and slow progressive 
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22. Podlesniy P. 2019. Absolute measurement of gene 
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24. Trullas R. 2019. Brain health and disease in the 
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1. Alarcón D, Pavia R, Ferrés A, Ruiz E, Coppola V, 
Miquel L, Artigas F, Bortolozzi A. 2019. Human Al-
pha-Synuclein Overexpression in Mouse Raphe Nuclei 
Induces Parkinson’s Disease Pathology. Reversal by 
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of the Spanish Society of Neuroscience. Santiago de 
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1. CIBERSAM Innovación Terapéurica (chairperson). 
Artigas F. XXII Congreso Nacional de Psiquiatría. 
Bilbao, Spain. 26-28.09.2019
2. Antisense oligonucleotides: Therapeutic oppor-
tunities in Parkinson’s disease (invited conference). 
Bortolozzi A. CINAC Hospital Universitario HM Puerta 
del Sur. Madrid, Spain. 19.11.2019
3. Ventral cingulate cortex, astrocytes and major 
depressive disorder. Development of a preclinical 
model. Bortolozzi A. Cicle de Seminaris IIB Sant Pau. 
Barcelona, Spain. 09.10.2019
4. Mitochondrial Respiratory Chain Complexes: Role 
in Liver Disease. Fernández-Checa JC. Mitochondrial 
Respiratory Chain Complexes: Role in Liver Diseases 
(Keck School of Medicine Seminars - University of 
California). Los Angeles, USA. 28.08.2019
5. Structural lipids in cell signaling and human disease. 
Fernández-Checa JC. Structural lipids in cell signaling 
and human disease (In-House IDIBAPS seminaries). 
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6. Structural lipids in cell signaling and human dise-
ase. Fernández-Checa JC. Seminario Grand Rounds. 
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7. Tratamiento Experimental de la Enfermedad de 
Niemann Pick C Con Éster de GSH. Fernández-Checa 
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8. Galectin-1 and pancreatic tumor microenvironment: 
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of the Hospital Clínic de Barcelona. Barcelona, Spain. 
13.03.2019
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12. Role of prefrontal 5-HT2A receptors in psycho-
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Santiago de Compostela. Santiago de Compostela, 
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ciated Parkinson’s disease. 18th National Meeting of 
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Spectrometry. XIX Reunión Científica de la Sociedad 
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2.  I2MC Group Leader Selection Inserm Tolouse. 
Llorente V. Toulouse, France. 01.03.2020
3. Peer-review of a research project for the Medi-
cal Research Council UK. Determining the role of 
coagulation proteases in the development of renal 
fibrosis. Moles AB. Swindon/London, United Kingdom. 
12.12.2019
4. Peer-review of an article for Histology and His-
topathology. Cathepsin-B dependent Autophagy 
Ameliorates Steatoheaptitis in Chronic Exercise Rats. 
Moles AB. Spain. 19.07.2019
5. Peer-review of an article for Kidney Research UK. 
Evaluation of nitrated-CXCL8 to monitor ischaemia 
reperfusion injury in kidney transplantation. Moles AB. 
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6. Peer-review of an article for Oxidative Medicine and 
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Kingdom. 14.10.2019
7. Peer-review of an article for the International Journal 
of Nephrology. The Role of Cathepsin B in Peritoneal 
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27.05.2019
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Artigas F. Barcelona, Spain. 29.03.2019
9. Subarea of Nervous System Diseases from the 
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Ciencia e Innovación. Bortolozzi A. Madrid, Spain. 
6-8.02.2019
10. XVI Reunión de la Asociación Española de Pan-
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1. Arteriosclerosis: Cholesterol, the silent killer. Mar-
tínez J. Science Week 2019. IIBB-CSIC Campus UB. 
Barcelona, Spain. 14.11.2019
2. Changing the expression of de brain genes with 
CRISPR and RNAi. Bortolozzi A. World Brain Week 
2019. Institut Municipal d’Educació de Barcelona. 
Barcelona, Spain. 11-15.03.2019
3. How are brain diseases studied? Inside the brain. 
Artigas F. World Brain Week 2019. Institut Municipal 
d’Educació de Barcelona. Barcelona, Spain. 11-15.03.2019
4. Liver regeneration: myth or reality. Moles AB. 
Science Week 2019. IIBB-CSIC Campus Clínic-UB. 
Barcelona, Spain. 13.11.2019
5. Mice depression studies. Tarrés M. World Brain 
Week 2019. Institut Municipal d’Educació de Barce-
lona. Barcelona, Spain. 11-15.03.2019
6. Molecular therapy. Can we silence the brain genes ex-
pression? Bortolozzi A. Science Week 2019. IIBB-CSIC 
Campus Clínic-UB. Barcelona, Spain. 14.11.2019
7.  Neuroscience and critical thinking: Myths and 
Reality. Pavía R. World Brain Week 2019. Institut 
Municipal d’Educació de Barcelona. Barcelona, Spain. 
11-15.03.2019
8.  Organization of the event. Mengod G & Cortés R. 
Science Week 2019. IIBB-CSIC Campus Clínic-UB. 
Barcelona, Spain. 11-14.11.2019
9. Science, credulity and charlatans. Closa D. Science 
Week 2019. IIBB-CSIC Campus Clínic-UB. Barcelona, 
Spain. 11.11.2019
10.  The human brain. Artigas F. World Brain Week 
2019. Institut Municipal d’Educació de Barcelona. 
Barcelona, Spain. 11-15.03.2019
11. The human brain. Vilaró T. Science Week 2019. II-
BB-CSIC Campus Clínic-UB. Barcelona, Spain. 13.11.2019
12. The human brain. Vilaró T. Stucom Centre d’Es-
tudis. Barcelona, Spain. 27.11.2019
13. Visits to the IIBB facilities (laboratories) for high 
school students. Observation of experimental tec-
hniques. Tarrés M, Pavía R, Miquel L, Solsona E, 
Petegnief V, Ochoa de Amezaga A, Bustamante E, 
Mengod G, Cortés R. Science Week 2019. IIBB-CSIC 
Campus Clínic-UB. Barcelona, Spain. 13-14.11.2019
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1. Hopeful advances in Alzheimer’s disease. Sanfeliu C. 
Lectures for the World Alzheimer’s Day 2019. Molins 
de Rei, Spain. 26.09.2019
2. Presentation of the book “100 secrets dels oceans”. 
Ciència Editada. Garcés E, Closa D, Calvo L. Barcelona, 
Spain. 02.05.2019
GENERAL AUDIENCE ACTIVITIES
3. Presentation of the book “Antropocè; la fi d’un 
món”. Sala de Convencions del Museu Cerdà de 
Puigcerdà. Closa D. Puigcerdà, Spain. 14.08.2019
4. Presentation of the book “Antropocè; la fi d’un 
món”. Biblioteca del Campus Universitari de Manresa 
(BCUM). Closa D. Manresa, Spain. 08.11.2019
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 01.02.2019 ElMedicoInteractivo.com. Press Article - 11 
investigadoras para visibilizar el papel de la mujer en 
la Ciencia. Bortolozzi A.
 05.02.2019 Infosalus.com. Press Article - Científicos 
españoles abren la puerta a nuevas dianas terapéu-
ticas contra la depresión. Bortolozzi A & Artigas F.
06.02.2019 Infosalus.com. Press Article - El CIBER 
destaca el papel y el trabajo de 11 de sus investigadoras 
para visibilizar a la mujer en la ciencia. Bortolozzi A.
25.02.2019 Clinicbarcelona.org (IDIBAPS). Press 
Article - Desarrollan un modelo animal de depresión 
basado en alterar la comunicación entre neuronas y 
astrocitos. Artigas F, Bortolozzi A, Fullana MN.
01.03.2019 Europa Press. Press Article - Iago Aspas 
‘acelera’ su recuperación en Barcelona. Hotter G.
 01.03.2019 La Voz de Galicia. Press Article - Iago 
Aspas, por el buen camino. Hotter G.
02.03.2019 Faro de Vigo. Press Article - Las pruebas 
médicas confirman la buena evolución de la lesión 
de Aspas. Hotter G.
 22.03.2019 Radio Molins de Rei. Award Ceremony – 
Premi Innovació. Sanfeliu C.
 29.03.2019 ElPais.com. Written Interview - Ketamina: 
anestesia, droga y esperanza contra la depresión. 
Artigas F.
 07.04.2019 ElPais.com. Written Interview - El sueño 
de una pastilla para ser feliz. Artigas F.
09.04.2019 TV Sant Cugat. TV Interview - Beneficios 
del ejercicio físico contra el envejecimiento cerebral. 
Programa en directo en el campo de deportes del 
club de rugbi de Sant Cugat. Sanfeliu C.
05.2019 Spanish National Research Council (CSIC). 
Press release - Hallan una posible nueva diana para 
el tratamiento de la toxicidad provocada por parace-
tamol. Torres S, García-Ruiz C, Fernández-Checa JC.
14.05.2019 imagenradio.com.mx. Press Article - Des-
cubren proteína para tratamiento de toxicidad por 
paracetamol. Torres S, García-Ruiz C, Fernández-C-
heca JC.
 14.05.2019 pulsoslp.com.mx. Press Article - Estudian 
proteína para tratamiento de toxicidad por paraceta-
mol. Torres S, García-Ruiz C, Fernández-Checa JC.
 14.05.2019 vertigopolitico.com. Press Article - Estu-
dian proteína para tratar toxicidad por paracetamol. 
Torres S, García-Ruiz C, Fernández-Checa JC.
14.05.2019 excelsior.com.mx. Press Article - Descubren 
proteína para tratamiento de toxicidad por paraceta-
mol. Torres S, García-Ruiz C, Fernández-Checa JC.
15.05.2019 Clinicbarcelona.org (IDIBAPS). Press Article 
- Hallan una posible nueva diana para el tratamiento 
de la toxicidad provocada por paracetamol. Torres 
S, García-Ruiz C, Fernández-Checa JC.
 15.05.2019 biotech-spain.com. Press Article - Hallan 
una posible nueva diana para el tratamiento de la 
toxicidad provocada por paracetamol. Torres S, 
García-Ruiz C, Fernández-Checa JC.
15.05.2019 boletin.ciberisciii.es. Press Article - Des-
criben un nuevo mediador mitocondrial en la he-
patotoxicidad inducida por paracetamol. Torres S, 
García-Ruiz C, Fernández-Checa JC.
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15.05.2019 Faro de Vigo. Press Article - Descubren 
una posible diana contra la toxicidad del paraceta-
mol. Torres S, García-Ruiz C, Fernández-Checa JC.
17.05.2019 pacientesenbuenasmanos.com. Press Arti-
cle - Nueva diana para el tratamiento de la toxicidad 
provocada por paracetamol. Torres S, García-Ruiz 
C, Fernández-Checa JC.
21.05.2019 jano.es. Press Article - Encuentran una 
posible diana para tratar la toxicidad por paraceta-
mol. Torres S, García-Ruiz C, Fernández-Checa JC.
07.07.2019 Campusmilenio.mx. Press Article - José 
Carlos Fernández-Checa será nombrado doctor ho-
noris causa por la UAM. Fernández-Checa JC.
 16.07.2019 Clinicbarcelona.org (IDIBAPS). Press Ar-
ticle - José Carlos Fernández-Checa, Doctor Honoris 
Causa por la Universidad Autónoma Metropolitana 
de México. Fernández-Checa JC.
 17.07.2019 La Vanguardia. Press Article - José Carlos 
Fernández-Checa, doctor honoris causa por Univer-
sidad de México. Fernández-Checa JC.
18.07.2019 ciberehd.org. Press Article - Fernández-C-
heca, doctor ‘honoris causa’ de la Universidad Autóno-
ma Metropolitana de Mexico. Fernández-Checa JC.
19.08.2019 Correofarmaceutico.com. Press Article 
- Descubren un nuevo biomarcador para predecir 
el riesgo cardiovascular en personas sin síntomas. 
Cortés-Llorente V & De Gonzalo D.
 19.08.2019 El Punt Avui. Press Article - Descubierto 
un nuevo biomarcador que predice con antelación el 
riesgo de desarrollar enfermedades cardiovasculares. 
Cortés-Llorente V & De Gonzalo D.
 19.08.2019 ciberisciii.es. Press Article - sLRP1 predi-
ce con mucha antelación el riesgo de enfermedad 
cardiovascular en personas que no presentan ningún 
síntoma. Cortés-Llorente V & De Gonzalo D.
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 19.08.2019 CEESSBLOG.blogspot.com. Press Article 
- Descubren un nuevo biomarcador para predecir 
el riesgo cardiovascular en personas sin síntomas. 
Cortés-Llorente V & De Gonzalo D.
 19.08.2019 Cadena Ser. Press Article - Una proteína 
alerta de ataques de corazón 10 años antes de que 
se produzcan. Cortés-Llorente V & De Gonzalo D.
 20.08.2019 saludadiario.es. Press Article - Nuevo 
biomarcador para predecir la enfermedad cardi-
ovascular con mucha antelación en pacientes sin 
ningún síntoma. Cortés-Llorente V, De Gonzalo D 
& Elosua R.
 20.08.2019 meneame.net. Press Article - Detectan 
una proteína que alerta de ataques de corazón 10 
años antes de que se produzcan. Cortés-Llorente V 
& De Gonzalo D.
20.08.2019 el Periódico. Press Article - Nou mètode 
per predir malalties cardiovasculars. Cortés-Llorente 
V, De Gonzalo D & Marrugar J.
 20.08.2019 El Punt Avui. Press Article - Un nou 
biomarcador prediu malalties cardiovasculars. Cor-
tés-Llorente V, De Gonzalo D & Marrugar J.
 20.08.2019 Diari de Girona. Press Article - Identifi-
quen un nou biomarcador per predirel risc cardio-
vascular. Cortés-Llorente V, De Gonzalo D, Elosua 
R & Marrugar J.
 20.08.2019 Spanish National Research Council 
(CSIC). Press release - Descubierto un biomar-
cador capaz de predecir el riesgo de desarrollar 
infarto agudo de miocardio. Cortés-Llorente V & 
De Gonzalo D.
 21.08.2019 La Sexta. Press Article - Científicos españoles 
descubren una proteína que predice infartos diez años de 
que se produzcan. Cortés-Llorente V & De Gonzalo D.
 30.08.2019 dicat.csic.es. Descubierto un biomarcador 
capaz de predecir el riesgo de desarrollar infarto agudo 
de miocardio. Cortés-Llorente V & De Gonzalo D.
 01.09.2019 Residència d’Investigadors. XX Anniver-
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